Snapshot from Aug 08, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / MaxCyte-Genentech cell therapy license
Business technology license partnership

MaxCyte-Genentech cell therapy license

Analysis based on 6 articles · First reported Jul 21, 2026 · Last updated Jul 22, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The partnership validates MaxCyte's platform technology and expands its commercial reach, likely boosting investor confidence. MaxCyte's stock rose 5.13% on the news, reflecting positive market reception.

Biotechnology Pharmaceuticals
Event Summary

MaxCyte, Inc. (Nasdaq: MXCT) announced a multi-platform technology license partnership with F. Hoffmann-La Roche — Genentech, a member of the Roche Group, to support the development of cell therapy programs. The license provides F. Hoffmann-La Roche — Genentech access to MaxCyte's ExPERT GTx platform and additional technologies across research, clinical development, and manufacturing workflows. The agreement is structured to support multiple ex vivo cell engineering programs. MaxCyte's Flow Electroporation technology enables delivery of genetic material into cells. The partnership aims to streamline cell therapy development from discovery to cGMP manufacturing. Financial terms were not disclosed. MaxCyte's stock closed up 5.13% on the announcement.

Key Actions
90 MaxCyte entered into license partnership F. Hoffmann-La Roche — Genentech
Entities Involved
stock
MaxCyte
MaxCyte is the licensor, gaining a high-profile partner in F. Hoffmann-La Roche — Genentech, which validates its technology and provides recurring revenue. The partnership enhances MaxCyte's reputation and market position in cell engineering.
Importance 100.0 Sentiment 70.0
subs
F. Hoffmann-La Roche — Genentech
F. Hoffmann-La Roche — Genentech gains access to MaxCyte's platform technologies to advance its cell therapy pipeline, potentially accelerating development timelines. The partnership is a strategic move to strengthen its cell therapy capabilities.
Importance 80.0 Sentiment 30.0
stock
Roche
Roche, as parent of F. Hoffmann-La Roche — Genentech, benefits indirectly from the partnership through F. Hoffmann-La Roche — Genentech's enhanced cell therapy development capabilities. The impact on Roche is modest.
Importance 40.0 Sentiment 20.0
per
Maher Masoud
Maher Masoud, as President and CEO of MaxCyte, announced the partnership and is credited with securing the deal, which reflects positively on his leadership.
Importance 30.0 Sentiment 40.0
Relationships
F. Hoffmann-La Roche — Genentech related ↔ Roche
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.